A股異動 | 西藏珠峯漲停 與中電建國際簽訂EPC框架協議書 加快鹽湖提鋰項目開發
格隆匯2月22日丨西藏珠峯(600338.SH)漲停,報34.95元創近一個半月新高,總市值320億元。西藏珠峯公吿稱,擬與藍曉科技簽訂藍曉吸附設備合同,合同總價6.5億元,擬與啟迪清源簽訂啟迪BOT合同,合同總價16億元;上述合同如正常履行,將有效促進公司間接控股阿根廷鋰鉀有限公司年產5萬噸碳酸鋰鹽湖提鋰建設項目的開發、建設。公吿同日,西藏珠峯為儘快實現間接控股的鹽湖提鋰項目開發,與中電建國際簽訂《阿根廷鋰鉀有限公司年產5萬噸碳酸鋰鹽湖提鋰建設項目礦建設計、採購和施工(EPC)框架協議書》。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.